Data gathered: January 21
AI Stock Analysis - Editas Medicine (EDIT)
Analysis generated January 21, 2025. Powered by Chat GPT.
Editas Medicine is a pioneering company within the field of genomic medicines. Leveraging CRISPR technology, the company aims to create transformative gene-editing therapies for patients with serious diseases. With a focus on developing innovative treatments that target the root cause of genetic disorders, Editas Medicine is at the forefront of biotechnological advances. However, recent financial and market performance indicate some challenges that need to be understood in depth.
Stock Alerts - Editas Medicine (EDIT)
 |
Editas Medicine | January 15 Price is up by 6.1% in the last 24h. |
|
Editas Medicine | January 13 Price is down by -5.6% in the last 24h. |
|
Editas Medicine | January 10 Price is down by -6% in the last 24h. |
|
Editas Medicine | January 8 Price is down by -5.5% in the last 24h. |
Alternative Data for Editas Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 36,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 87 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,033 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 40 | Sign up | Sign up | Sign up |
| Business Outlook | 51 | Sign up | Sign up | Sign up |
| Linkedin Employees | 336 | Sign up | Sign up | Sign up |
About Editas Medicine
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| Price | $1.21 |
| Target Price | Sign up |
| Volume | 2,160,000 |
| Market Cap | $101M |
| Year Range | $1.14 - $6.04 |
| Dividend Yield | 0% |
| Analyst Rating | 24% buy |
| Industry | Biotechnology |
In the news
 |
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)January 15 - SeekingAlpha |
 |
Editas Medicine stock hits 52-week low at $1.16 amid steep declineJanuary 13 - Investing.com |
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesJanuary 13 - GlobeNewswire |
|
 |
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 5 - Yahoo |
 |
Critical Review: Editas Medicine (NASDAQ:EDIT) & JATT Acquisition (NYSE:JATT)January 5 - ETF Daily News |
 |
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Rises By 5.4%January 1 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 61,000 | 18M | -18M | -62M | -61M | -0.750 |
| Q2 '24 | 510,000 | 18M | -18M | -68M | -70M | -0.820 |
| Q1 '24 | 1.1M | 19M | -18M | -62M | -66M | -0.760 |
| Q4 '23 | 62M | 14M | 47M | -19M | -22M | -0.230 |
| Q3 '23 | 5.3M | 15M | -9.7M | -45M | -45M | -0.550 |
Insider Transactions View All
| Mei Baisong filed to sell 133,354 shares at $2.1. December 5 '24 |
| O'Neill Gilmore Neil filed to sell 312,106 shares at $2.1. December 5 '24 |
| Mei Baisong filed to sell 133,895 shares at $3.4. September 6 '24 |
| O'Neill Gilmore Neil filed to sell 313,724 shares at $3.4. September 6 '24 |
| Burkly Linda filed to sell 73,136 shares at $5.4. July 26 '24 |
Similar companies
Read more about Editas Medicine (EDIT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Editas Medicine?
The Market Cap of Editas Medicine is $101M.
What is the current stock price of Editas Medicine?
Currently, the price of one share of Editas Medicine stock is $1.21.
How can I analyze the EDIT stock price chart for investment decisions?
The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.
Does EDIT offer dividends to its shareholders?
As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Editas Medicine?
Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.